Black Box Warning (May 2017): RISK OF TOE / LOWER LIMB AMPUTATION Notes: Canagliflozin underwent a post-marketing CANVAS cardiovascular outcomes trial (the Canagliflozin Cardiovascular Assessment Study) that ended in 2017 (Karagiannis et al, 2017
For Canadians dealing with obesity now, that wait feels impossibly long
[DOI] [PMC free article] [PubMed] [Google Scholar] 15.Chen X., Sun X., Wang C., He H
It is not appropriate for individuals with active cancer, certain pituitary conditions, or other contraindications
GLP-1RA showed a significant reduction in HF hospitalization events in the subgroup of the RCT population compared to placebo (HR 0.60, 95% CI: 0.510.72
But if people ask me, Would you take it? I would say no, citing worries about the long-term effects on things like tumor growth and whether it can enhance already proven levers like good nutrition, sleep, and rehab